ETFsXtrackers MSCI Thailand UCITS ETF 1C
Xtrackers
Xtrackers MSCI Thailand UCITS ETF 1C
XCS4 LSEAccumulatingLuxembourg
Last close · EUR
23.79EUR
-2.03% · -€0.49
Published closes: 29 Oct 2026 - 30 Oct 2026
30 Oct 2026, close
XCS4Base
- Fund charges
- Not publishedFee basis unverified
- Fund size
- Not published
- Return 1Y
- +18.0%
- Sharpe 3Y
- 0.27
- Volatility 1Y
- 20.1%annualised
- Holdings
- 19Fund holdings
Performance
Compare
- XCS4+18.0%
- Price, EUR
Returns
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|
| XCS4 | -1.4% | -4.1% | -1.5% | +20.5% | +18.0% | +26.0% | +19.8% |
| MSCI World | +0.4% | +4.9% | +10.8% | +16.3% | +15.9% | +75.5% | +71.2% |
| Gap to MSCI World | -1.8% | -8.9% | -12.3% | +4.2% | +2.1% | -49.5% | -51.4% |
Risk and return
Sharpe ratio · 3Y
0.27
Below MSCI World · 1.24- Return p.a.
- +6.5%
- Volatility
- 19.7%
- Max loss
- -30.5%Apr 2025
Sharpe vs indices
MSCI World
1.24
S&P 500
1.21
STOXX Europe 600
1.04
MSCI Emerging Markets IMI
0.93
CAC 40
0.37
XCS4
0.27
Method
Weekly EUR returns from adjusted closes. Sharpe is the annualised excess return over the euro overnight rate (Xtrackers II EUR Overnight Rate Swap UCITS ETF 1C) divided by its volatility. Max loss uses daily closes.
Top holdings
- Top 10
- 77.0%
- Holdings
- 19
- As of
- 1DELTA ELECTRONICS THAI NVDRTH0528010R1817.23%
- 2PTT PCL NVDRTH0646010R1811.43%
- 3ADVANCED INFO SERVICE NVDRTH0268010R118.89%
- 4AIRPORTS OF THAILAND PC NVDRTH0765010R166.39%
- 5GULF DEVELOPMENT PCL NVDRTHC903010R146.20%
- 6CP ALL PCL NVDRTH0737010R156.15%
- 7PTT EXPLOR + PROD PCL NVDRTH0355010R165.80%
- 8BANGKOK DUSIT MED SERVI NVDRTH0264010R105.72%
- 9SIAM CEMENT PCL NVDRTH0003010R125.00%
- 10KRUNG THAI BANK NVDRTH0150010R114.16%
Countries
Classified 100.0%
Thailand100.0%
- Largest
- 100.0%Thailand
- Top 3
- 100.0%
- Effective number
- 1.01 / HHI
Market cap
Weight vs holdings
77.0%of the fund sits in the top 10 holdings
77.0%23.0%
WeightHoldings
109
- Holdings 1-10
- Holdings 11-19
Size split
Not published
Compare ETFs in Copio.
Factual research, without a suitability score or investment recommendation. Past relationships can change.
